arrow
G

Gregory M. Sullivan

University of Tennessee System
H指数:38
被引数:5,883

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults

首次人体、Ⅰ期、随机、双盲、安慰剂对照研究,评估Fc修饰的抗CD154单克隆抗体TNX-1500在健康成人中单次递增剂量的安全性、耐受性、药代动力学和药效动力学

2026-04-290
PRE
Steady-State Pharmacokinetic Properties of TNX-102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open-Label Trial

盐酸环苯扎普林(HCl)舌下片剂TNX-102 SL的稳态药代动力学特性及每日给药方案在健康志愿者中的研究:一项随机、开放标签试验

2026-04-080
OA
Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine

Lederman, S.; Arnold, L.M.; Vaughn, B.; Engels, J.M.; Kelley, M.; Sullivan, G.M. 通过靶向非恢复性睡眠缓解纤维肌痛的疼痛:一项关于睡前舌下环苯扎林的三期随机试验。Pain Med. 2025, pnaf089. [Google Scholar] [CrossRef]

2025-07-0111
OA
Development and evaluation of a multimodal marker of major depressive disorder
2018-08-1640
OAAI